中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 5
May  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(5): 1148-1151

Role and mechanism of interleukin-35 in hepatitis B virus-related diseases

DOI: 10.3969/j.issn.1001-5256.2022.05.036

  • Department of Infectious Diseases, Tangdu Hospital, Fourth Military Medical University & The Second Affiliated Hospital of Air Force Medical University, Xi'an 710038, China

Research funding:

National Natural Science Foundation of China (31370856);

National Natural Science Foundation of China (81671555);

National Science and Technology Major Project of China for Prevention and Treatment of Serious Infectious Diseases (2017ZX10202203-007-003);

National Science and Technology Major Project of China for Prevention and Treatment of Serious Infectious Diseases (2017ZX10105011-004)

More Information
  • Corresponding author: ZHANG Ye, zhangyefmmu@hotmail.com(ORCID: 0000-0002-2573-5471)
  • Received Date: 2021-09-09
  • Published Date: 2022-05-20
    Abstract
  • Interleukin-35 (IL-35) is an immunosuppressive cytokine mainly secreted by regulatory T cells and regulatory B cells and is involved in the pathogenesis of infectious diseases, tumors, and autoimmune diseases. This article summarizes the immunoregulatory role and mechanism of IL-35 in hepatitis B, liver cirrhosis, liver failure, and hepatocellular carcinoma caused by hepatitis B virus (HBV) infection. The analysis shows that IL-35 is a "double-edged sword" in HBV-related diseases, and it can not only promote the chronicity of infection and the progression of hepatocellular carcinoma, but also alleviate liver inflammation and inhibit liver fibrosis.

     

    • FullText(HTML)
  • loading
    • References(52)
  • [1]
    CHOI JK, EGWUAGU CE. Interleukin 35 regulatory B cells[J]. J Mol Biol, 2021, 433(1): 166607. DOI: 10.1016/j.jmb.2020.07.019.
    [2]
    LIU K, HUANG A, NIE J, et al. IL-35 regulates the function of immune cells in tumor microenvironment[J]. Front Immunol, 2021, 12: 683332. DOI: 10.3389/fimmu.2021.683332.
    [3]
    XIN PL, JIE LF, CHENG Q, et al. Pathogenesis and function of interleukin-35 in rheumatoid arthritis[J]. Front Pharmacol, 2021, 12: 655114. DOI: 10.3389/fphar.2021.655114.
    [4]
    LI X, LIU X, WANG W. IL-35: A novel immunomodulator in hepatitis B virus-related liver diseases[J]. Front Cell Dev Biol, 2021, 9: 614847. DOI: 10.3389/fcell.2021.614847.
    [5]
    HU S, LIAN PP, HU Y, et al. The role of IL-35 in the pathophysiological processes of liver disease[J]. Front Pharmacol, 2020, 11: 569575. DOI: 10.3389/fphar.2020.569575.
    [6]
    TAIT WOJNO ED, HUNTER CA, STUMHOFER JS. The immunobiology of the Interleukin-12 family: Room for discovery[J]. Immunity, 2019, 50(4): 851-870. DOI: 10.1016/j.immuni.2019.03.011.
    [7]
    COLLISON LW, WORKMAN CJ, KUO TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function[J]. Nature, 2007, 450(7169): 566-569. DOI: 10.1038/nature06306.
    [8]
    BEHZADI P, BEHZADI E, RANJBAR R. IL-12 family cytokines: General characteristics, pathogenic microorganisms, receptors, and signalling pathways[J]. Acta Microbiol Immunol Hung, 2016, 63(1): 1-25. DOI: 10.1556/030.63.2016.1.1.
    [9]
    DIXON KO, van der KOOIJ SW, VIGNALI DA, et al. Human tolerogenic dendritic cells produce IL-35 in the absence of other IL-12 family members[J]. Eur J Immunol, 2015, 45(6): 1736-1747. DOI: 10.1002/eji.201445217.
    [10]
    COLLISON LW, DELGOFFE GM, GUY CS, et al. The composition and signaling of the IL-35 receptor are unconventional[J]. Nat Immunol, 2012, 13(3): 290-299. DOI: 10.1038/ni.2227.
    [11]
    DAMBUZA IM, HE C, CHOI JK, et al. IL-12p35 induces expansion of IL-10 and IL-35-expressing regulatory B cells and ameliorates autoimmune disease[J]. Nat Commun, 2017, 8(1): 719. DOI: 10.1038/s41467-017-00838-4.
    [12]
    LIU J, HAO S, CHEN X, et al. Human placental trophoblast cells contribute to maternal-fetal tolerance through expressing IL-35 and mediating iT(R)35 conversion[J]. Nat Commun, 2019, 10(1): 4601. DOI: 10.1038/s41467-019-12484-z.
    [13]
    WANG W, WEI C, CHENG Z, et al. Aberrant Th2 immune responses are associated with a reduced frequency of IL-35-induced regulatory T cells after allergen exposure in patients with allergic asthma[J]. Allergy Asthma Immunol Res, 2020, 12(6): 1029-1045. DOI: 10.4168/aair.2020.12.6.1029.
    [14]
    GUO H, ZHAO N, GAO H, et al. Mesenchymal stem cells overexpressing interleukin-35 propagate immunosuppressive effects in mice[J]. Scand J Immunol, 2017, 86(5): 389-395. DOI: 10.1111/sji.12613.
    [15]
    LI Y, PAN X, PENG X, et al. Adenovirus-mediated interleukin-35 gene transfer suppresses allergic airway inflammation in a murine model of asthma[J]. Inflamm Res, 2015, 64(10): 767-774. DOI: 10.1007/s00011-015-0858-1.
    [16]
    TEYMOURI M, PIRRO M, FALLARINO F, et al. IL-35, a hallmark of immune-regulation in cancer progression, chronic infections and inflammatory diseases[J]. Int J Cancer, 2018, 143(9): 2105-2115. DOI: 10.1002/ijc.31382.
    [17]
    XUE H, LIN F, TAN H, et al. Overrepresentation of IL-10-expressing B cells suppresses cytotoxic CD4+ T cell activity in HBV-induced hepatocellular carcinoma[J]. PLoS One, 2016, 11(5): e0154815. DOI: 10.1371/journal.pone.0154815.
    [18]
    DAMO M, JOSHI NS. T(reg) cell IL-10 and IL-35 exhaust CD8(+) T cells in tumors[J]. Nat Immunol, 2019, 20(6): 674-675. DOI: 10.1038/s41590-019-0389-y.
    [19]
    CHENG ST, YUAN D, LIU Y, et al. Interleukin-35 level is elevated in patients with chronic hepatitis B virus infection[J]. Int J Med Sci, 2018, 15(2): 188-194. DOI: 10.7150/ijms.21957.
    [20]
    RIBEIRO C, MARTINELLI KG, de MELLO V, et al. Cytokine, genotype, and viral load profile in the acute and chronic hepatitis B[J]. Viral Immunol, 2020, 33(10): 620-627. DOI: 10.1089/vim.2020.0176.
    [21]
    ZHOU Y, ZHANG H, LI Y. IL-35 expression in peripheral blood CD4(+) T cells from chronic hepatitis B virus-infected patients directly correlates with virus load[J]. Cytokine, 2015, 73(1): 169-175. DOI: 10.1016/j.cyto.2015.02.003.
    [22]
    TAO NN, GONG R, CHEN X, et al. Interleukin-35 stimulates hepatitis B virus transcription and replication by targeting transcription factor HNF4α[J]. J Gen Virol, 2018, 99(5): 645-654. DOI: 10.1099/jgv.0.001050.
    [23]
    YANG J, MA C, ZHAO Y, et al. Hepatitis B virus core particles containing a conserved region of the G Protein Combined with Interleukin-35 protected mice against respiratory syncytial virus infection without vaccine-enhanced immunopathology[J]. J Virol, 2020, 94(13): e00007-20. DOI: 10.1128/JVI.00007-20.
    [24]
    LIU Y, LUO Y, ZHU T, et al. Regulatory B cells dysregulated T cell function in an IL-35-dependent way in patients with chronic hepatitis B[J]. Front Immunol, 2021, 12: 653198. DOI: 10.3389/fimmu.2021.653198.
    [25]
    WAN Z, ZHOU Z, LIU Y, et al. Regulatory T cells and T helper 17 cells in viral infection[J]. Scand J Immunol, 2020, 91(5): e12873. DOI: 10.1111/sji.12873.
    [26]
    SHAO X, MA J, JIA S, et al. Interleukin-35 suppresses antiviral immune response in chronic hepatitis B virus infection[J]. Front Cell Infect Microbiol, 2017, 7: 472. DOI: 10.3389/fcimb.2017.00472.
    [27]
    YANG L, JIA S, SHAO X, et al. Interleukin-35 modulates the balance between viral specific CD4(+)CD25(+) CD127(dim/-) regulatory T cells and T helper 17 cells in chronic hepatitis B virus infection[J]. Virol J, 2019, 16(1): 48. DOI: 10.1186/s12985-019-1158-0.
    [28]
    TENG DK, LIU Y, LV YF, et al. Elevated interleukin-35 suppresses liver inflammation by regulation of T helper 17 cells in acute hepatitis B virus infection[J]. Int Immunopharmacol, 2019, 70: 252-259. DOI: 10.1016/j.intimp.2019.02.048.
    [29]
    MCLANE LM, ABDEL-HAKEEM MS, WHERRY EJ. CD8 T cell exhaustion during chronic viral infection and cancer[J]. Annu Rev Immunol, 2019, 37: 457-495. DOI: 10.1146/annurev-immunol-041015-055318.
    [30]
    LI X, TIAN L, DONG Y, et al. IL-35 inhibits HBV antigen-specific IFN-γ-producing CTLs in vitro[J]. Clin Sci (Lond), 2015, 129(5): 395-404. DOI: 10.1042/CS20140511.
    [31]
    DONG Y, LI X, YU Y, et al. JAK/STAT signaling is involved in IL-35-induced inhibition of hepatitis B virus antigen-specific cytotoxic T cell exhaustion in chronic hepatitis B[J]. Life Sci, 2020, 252: 117663. DOI: 10.1016/j.lfs.2020.117663.
    [32]
    XIANG XG, XIE Q. IL-35: A potential therapeutic target for controlling hepatitis B virus infection[J]. J Dig Dis, 2015, 16(1): 1-6. DOI: 10.1111/1751-2980.12218.
    [33]
    LUO M, PENG H, CHEN P, et al. The immunomodulatory role of interleukin-35 in fibrotic diseases[J]. Expert Rev Clin Immunol, 2019, 15(4): 431-439. DOI: 10.1080/1744666X.2019.1564041.
    [34]
    LI T, HUANG Y, LIU P, et al. Lower plasma levels of IL-35 in patients with primary biliary cirrhosis[J]. Tohoku J Exp Med, 2018, 244(2): 123-131. DOI: 10.1620/tjem.244.123.
    [35]
    SHI M, WEI J, DONG J, et al. Function of interleukin-17 and -35 in the blood of patients with hepatitis B-related liver cirrhosis[J]. Mol Med Rep, 2015, 11(1): 121-126. DOI: 10.3892/mmr.2014.2681.
    [36]
    HU H, FU Y, LI M, et al. Interleukin-35 pretreatment attenuates lipopolysaccharide-induced heart injury by inhibition of inflammation, apoptosis and fibrotic reactions[J]. Int Immunopharmacol, 2020, 86: 106725. DOI: 10.1016/j.intimp.2020.106725.
    [37]
    TSUDA M, ZHANG W, YANG GX, et al. Deletion of interleukin (IL)-12p35 induces liver fibrosis in dominant-negative TGFβ receptor type Ⅱ mice[J]. Hepatology, 2013, 57(2): 806-816. DOI: 10.1002/hep.25829.
    [38]
    WANG W, GUO H, LI H, et al. Interleukin-35 Gene-modified mesenchymal stem cells protect concanavalin A-induced fulminant hepatitis by decreasing the interferon gamma level[J]. Hum Gene Ther, 2018, 29(2): 234-241. DOI: 10.1089/hum.2017.171.
    [39]
    KODA Y, NAKAMOTO N, CHU PS, et al. Plasmacytoid dendritic cells protect against immune-mediated acute liver injury via IL-35[J]. J Clin Invest, 2019, 129(8): 3201-3213. DOI: 10.1172/JCI125863.
    [40]
    CHEN L, SUN W, WANG Y, et al. Lower levels of interleukin-35 in patients with prophase of liver failure are associated with progression to liver failure[J]. Ann Palliat Med, 2021, 10(8): 9174-9183. DOI: 10.21037/apm-21-1680.
    [41]
    YANG L, ZHANG Q, SONG J, et al. Interleukin-35 suppresses CD8(+) T cell activity in patients with viral hepatitis-induced acute-on-chronic liver failure[J]. Dig Dis Sci, 2020, 65(12): 3 614-3623. DOI: 10.1007/s10620-020-06077-w.
    [42]
    GAO Y, LIANG ZJ, FU J. Influence of interleukin-35 on peripheral CD8+ T cell function in patients with acute-on-chronic liver failure[J]. J Clin Hepatol, 2019, 35(9): 2011-2016. DOI: 10.3969/j.issn.1001-5256.2019.09.025.

    高艺, 梁志军, 符健. IL-35对慢加急性肝衰竭患者外周血CD8+T淋巴细胞功能的影响[J]. 临床肝胆病杂志, 2019, 35(9): 2011-2016. DOI: 10.3969/j.issn.1001-5256.2019.09.025.
    [43]
    KOURKO O, SEAVER K, ODOARDI N, et al. IL-27, IL-30, and IL-35: A cytokine triumvirate in cancer[J]. Front Oncol, 2019, 9: 969. DOI: 10.3389/fonc.2019.00969.
    [44]
    LIU K, HUANG A, NIE J, et al. IL-35 regulates the function of immune cells in tumor microenvironment[J]. Front Immunol, 2021, 12: 683332. DOI: 10.3389/fimmu.2021.683332.
    [45]
    XUE W, YAN D, KAN Q. Interleukin-35 as an emerging player in tumor microenvironment[J]. J Cancer, 2019, 10(9): 2074-2082. DOI: 10.7150/jca.29170.
    [46]
    LONG J, GUO H, CUI S, et al. IL-35 expression in hepatocellular carcinoma cells is associated with tumor progression[J]. Oncotarget, 2016, 7(29): 45678-45686. DOI: 10.18632/oncotarget.10141.
    [47]
    FU YP, YI Y, CAI XY, et al. Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection[J]. Br J Cancer, 2016, 114(7): 767-776. DOI: 10.1038/bjc.2016.47.
    [48]
    HE Y, PEI JH, LI XQ, et al. IL-35 promotes EMT through STAT3 activation and induces MET by promoting M2 macrophage polarization in HCC[J]. Biochem Biophys Res Communl, 2021, 559: 35-41. DOI: 10.1016/j.bbrc.2021.04.050.
    [49]
    LIU X, REN H, GUO H, et al. Interleukin-35 has a tumor-promoting role in hepatocellular carcinoma[J]. Clin Exp Immunol, 2021, 203(2): 219-229. DOI: 10.1111/cei.13535.
    [50]
    YANG L, SHAO X, JIA S, et al. Interleukin-35 dampens CD8(+) T cells activity in patients with non-viral hepatitis-related hepatocellular carcinoma[J]. Front Immunol, 2019, 10: 1032. DOI: 10.3389/fimmu.2019.01032.
    [51]
    ZHANG Q, YANG L, LIU S, et al. Interleukin-35 suppresses interleukin-9-secreting CD4(+) T cell activity in patients with hepatitis B-related hepatocellular carcinoma[J]. Front Immunol, 2021, 12: 645835. DOI: 10.3389/fimmu.2021.645835.
    [52]
    YAZDANI Z, RAFIEI A, GOLPOUR M, et al. IL-35, a double-edged sword in cancer[J]. J Cell Biochem, 2020, 121(3): 2064-2076. DOI: 10.1002/jcb.29441.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (490) PDF downloads(50) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return